Bristol Myers Squibb reported third-quarter 2026 results on Oct. 29 and raised its full-year revenue outlook. The company attributed its strong performance to growth in its portfolio and disciplined execution, while also pointing to regulatory approvals and positive late-stage trial results across several areas.
- Outlook: The company raised its revenue outlook for the full year. The amount of the increase and the revised revenue range are not included in the supplied materials.
- Quarterly performance: Bristol Myers described its third-quarter results as strong, citing growth across its portfolio and disciplined execution. Specific revenue, earnings and product-level figures are not included here.
- Pipeline: The company highlighted regulatory approvals and positive registrational data across multiple therapeutic areas. The supplied text does not identify the medicines, indications or trial results.
- Investor presentation: Bristol Myers posted a presentation covering financial and operating initiatives for its results call. It is intended to be read alongside the earnings release.
- Results call: The company scheduled a conference call and webcast for 8 a.m. Eastern time on Oct. 29.
The central change for investors is the higher full-year revenue outlook. The excerpt does not provide the updated forecast or the underlying quarterly figures needed to assess the size of the increase.